Back to News
Market Impact: 0.2
SciBase receives additional order from Castle Biosciences, advancing the collaboration
Source: PR Newswire
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
SciBase Holding announced an additional order to accelerate its ongoing clinical study involving its AI-based dermatology detection and prevention devices. The announcement signals continued clinical-study activity and customer demand, but the provided release excerpt does not disclose the order value, study scope, timeline, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
SCIB0.55
More News
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- AI Doubts Spread Cracks in Equities, Credit Markets: Evening Briefing Americas
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- CrowdStrike CEO's alarming prediction — plus, the sell-off spreads beyond tech
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.